2 completed, 1 recruiting, 1 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Priscilla Hsue, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial) Bempedoic acid, Placebo - Dyslipidemias, Cardiovascular Diseases | Phase 2 | Recruiting | Priscilla Hsue, MD | 121 | 2023-03-01 | 2025-12-17 |
| Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial VB-201, Placebo - Inflammation, HIV Infection | Phase 1 / Phase 2 | Withdrawn | Priscilla Hsue, MD | 2022-07-01 | 2022-09-15 | |
| Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients COVID-19 Convalescent Plasma (CCP), Placebo - COVID-19, Sars-CoV2 | Phase 2 | Completed | Priscilla Hsue, MD | 34 | 2020-06-09 | 2022-10-07 |
| Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Canakinumab, Placebo - HIV, Cardiovascular Disease | Phase 2 | Completed | Priscilla Hsue, MD | 43 | 2015-09-01 | 2023-04-20 |
Cardiovascular Diseases (3) · HIV Infections (2) · Atherosclerosis (1) · COVID-19 (1) · Dyslipidemias (1) · Inflammation (1)
1-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine (1) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (1) · COVID-19 Serotherapy (1) · canakinumab (1)
United States (4)